within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BC04_Flurbiprofen;

model Flurbiprofen
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.575e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.00014000000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0001,
    k12 = 1.4194444444444443e-06,
    k21 = 1.4194444444444443e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Flurbiprofen</td></tr><tr><td>ATC code:</td><td>S01BC04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.14</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.081</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used primarily for its analgesic, anti-inflammatory, and antipyretic properties. It is typically indicated for the treatment of pain, such as sore throat, musculoskeletal pain, and ocular inflammation. As an eye drop (S01BC04), it is approved and used for prevention and treatment of postoperative miosis and inflammation after cataract surgery.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for flurbiprofen reported in healthy adult subjects after intravenous administration.</p><h4>References</h4><ol><li><p>Zhang, J, et al., &amp; An, H (2018). Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. <i>Journal of pain research</i> 11 3061–3070. DOI:<a href=\"https://doi.org/10.2147/JPR.S176475\">10.2147/JPR.S176475</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30555252/\">https://pubmed.ncbi.nlm.nih.gov/30555252</a></p></li><li><p>Kumpulainen, E, et al., &amp; Kokki, H (2010). Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. <i>British journal of clinical pharmacology</i> 70(4) 557–566. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2010.03720.x\">10.1111/j.1365-2125.2010.03720.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20840447/\">https://pubmed.ncbi.nlm.nih.gov/20840447</a></p></li><li><p>Loisios-Konstantinidis, I, et al., &amp; Dressman, J (2020). Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen. <i>Pharmaceutics</i> 12(11) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics12111049\">10.3390/pharmaceutics12111049</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33147873/\">https://pubmed.ncbi.nlm.nih.gov/33147873</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01BC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Flurbiprofen;
